---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-24-000069"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:16:26.585266+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports 40% ORR, 80% DCR from IMM-1-104 combo in pancreatic cancer

## Summary
- First patient had complete response; second unconfirmed partial; third/fourth stable disease; fifth equivocal progressive disease.
- 80% disease control rate and 40% overall response rate (RECIST) in first five patients; all remain on treatment.
- DSMB approved enrollment of additional patients at 320 mg QD; dosing has begun.
- Initial data from another Phase 2a arm of IMM-1-104 and Phase 1 data for IMM-6-415 expected by year-end 2024.

## SEC filing metadata
- accession: 0001790340-24-000069
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000069/0001790340-24-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000069/imrx-20240912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-24-000069
- JSON: https://secwatch.observer/filing/0001790340-24-000069.json
- Plain text: https://secwatch.observer/filing/0001790340-24-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.